Free Trial
NYSEAMERICAN:HEB

Hemispherx BioPharma (HEB) Stock Price, News & Analysis

Hemispherx BioPharma logo
$6.70 -1.68 (-20.05%)
As of 06/13/2025

About Hemispherx BioPharma Stock (NYSEAMERICAN:HEB)

Key Stats

Today's Range
$5.80
$9.00
50-Day Range
$0.09
$8.38
52-Week Range
$1.69
$14.81
Volume
7,639 shs
Average Volume
102,599 shs
Market Capitalization
$16.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma and malignant melanoma. The company was founded in 1990 and is headquartered in Orlando, Florida.

Receive HEB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hemispherx BioPharma and its competitors with MarketBeat's FREE daily newsletter.

HEB Stock News Headlines

New Rule Hits in July — The Smart Money Already Moved
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
Hemispherx Biopharma earnings preview: what Wall Street is expecting
H-E-B hosting hiring fairs
H-E-B opens doors to new Georgetown grocery store
See More Headlines

HEB Stock Analysis - Frequently Asked Questions

Hemispherx BioPharma's stock was trading at $0.2170 at the start of the year. Since then, HEB stock has increased by 2,987.6% and is now trading at $6.70.
View the best growth stocks for 2025 here
.

Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) announced its quarterly earnings data on Thursday, August, 15th. The specialty pharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.70) by $0.63. The specialty pharmaceutical company had revenue of $0.03 million for the quarter.

Hemispherx BioPharma's stock reverse split on the morning of Tuesday, June 11th 2019.The 1-44 reverse split was announced on Friday, May 31st 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 10th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

Shares of HEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Hemispherx BioPharma investors own include NewLink Genetics (NLNK), Goodrich Petroleum (GDPMQ), Biocept (BIOC), CTI BioPharma (CTIC), Inovio Pharmaceuticals (INO), Palatin Technologies (PTN) and Ayala Pharmaceuticals (ADXS).

Company Calendar

Last Earnings
8/15/2019
Today
6/30/2025

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NYSEAMERICAN:HEB
Previous Symbol
NYSE:HEB
Fax
N/A
Employees
31
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$16.36 million
Optionable
Not Optionable
Beta
N/A
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NYSEAMERICAN:HEB) was last updated on 6/30/2025 by MarketBeat.com Staff
From Our Partners